ISPE 2025 to Feature Analysis Group Research
Event: 41st International Society for Pharmacoepidemiology (ISPE) Annual Meeting Dates: 22–26 August 2025 Host: International Society for Pharmacoepidemiology (ISPE) Location: Washington, DC
Analysis Group, a global leader in drug safety epidemiology and regulatory real-world evidence (RWE), will present two podium presentations and four research posters at the 41st annual meeting of the International Society for Pharmacoepidemiology (ISPE).
Three Analysis Group vice presidents will participate in podium presentations at the meeting:
Sunday, August 24, 10:30 a.m.–12:00 p.m. ET, Room 202AB
- Vice President Marianne Cunnington will co-moderate a session of presentations on pregnancy epidemiology titled “The Algorithm Awakens: Pregnancy and Data”
Monday, August 25, 5:00 p.m. ET, Room 208AB
- Vice President Rose Chang will be the presenting author of “Development of a Rule-based Definition of Clinically Ready for Discharge Status in Hospitalized Patients with Complicated Urinary Tract Infection Treated with Intravenous Carbapenems”
Monday, August 25, 5:15 p.m. ET, Room 208AB
- Vice President Priyanka Bobbili will be the presenting author of “Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results”
Additionally, researchers from Analysis Group – including Managing Principals Mei Sheng Duh and Maral DerSarkissian, Vice Presidents Marianne Cunnington and Lynn Huynh, and Managers Catherine Nguyen, Aolin Wang, and Mu Cheng – will present four posters at the meeting on the following topics:
Poster Session A: Sunday, August 24, 8:00 a.m.–6:00 p.m. ET
- Leveraging Real-World Data for Regulatory Commitment: Methodological Considerations in a Post-Approval Safety Study Evaluating the Risk of Atrial Fibrillation (AF) Following Respiratory Syncytial Virus (RSV) Vaccination
- Real-World Effectiveness of Ravulizumab in Adults With aHUS who Switched to Ravulizumab Within 3 Months of Eculizumab Treatment (aHUS IMPACT)
Poster Session B: Monday, August 25, 8:00 a.m.–6:00 p.m. ET
- Integrating the Patient Perspective Within Real-World Evidence: A Case Study Linking Routinely Collected Patient-Reported Outcomes and Electronic Health Records from Mass General Brigham Healthcare System
Poster Session C: Tuesday, August 26, 8:00 a.m.–1:30 p.m. ET
- Association of Hepatitis B Surface Antigen Loss (HBsAg) with Clinical Outcomes Among Patients with Chronic Hepatitis B Virus (HBV) Infection: A Retrospective Cohort Study in the United States (US)
Further details on the podium presentations and posters are available in our 2025 ISPE Presentation Guide. Analysis Group is a proud gold sponsor of this meeting.
Associated People
Marianne Cunnington
Vice PresidentDr. Cunnington has over 20 years of experience as a pharmaceutical industry epidemiologist. She specializes in the generation of real-world evidence (RWE) in support of the development and lifecycle management of pharmaceutical and vaccine products, with particular focus on regulatory risk management strategies and product benefit risk assessments. Dr. Cunnington focuses on regulatory epidemiology with design and execution of real-world post-marketing safety studies, as well as real-world studies to support the approval of new products in the context of innovative regulatory pathways. Her research expertise includes design, negotiation, and execution of real-world components of risk management plans for multiple new product submission with regulators across multiple geographies (US, UK, Europe, Japan, South Korea), post approval safety studies in the EU, post-marketing requirement and commitment studies in the US, and pregnancy registries. Prior to joining Analysis Group, Dr. Cunnington held several senior epidemiology positions within Novartis and GlaxoSmithKline (GSK). At GSK, she chaired the peer review forum for all pharmaceutical real world evidence projects, provided epidemiological expertise for the GSK’s Global Safety Board and was a managing board member of the Innovative Medicines Initiative’s public-private partnership, building an integrated European real-world data network to monitor medication safety in pregnancy. Dr. Cunnington is currently an elected board member representing European industry and service providers for the International Society of Pharmacoepidemiology.